Semaglutide for Medical Weight Loss in Coastal Georgia

Medically reviewed by Donald L. Gates, MD — Last reviewed June 2026

★ 4.6 · 44 Google reviews across Savannah, Pooler & Hinesville

Semaglutide for Medical Weight Loss in Coastal Georgia

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist medication that has been FDA-approved for use in weight management in eligible adults. At Scale Solutions, we prescribe semaglutide in its FDA-approved brand-name forms—Ozempic® and Wegovy®, both manufactured by Novo Nordisk—under the clinical supervision of Donald L. Gates, MD, who has practiced bariatric medicine since 1999. We serve patients across Coastal Georgia, including Savannah, Pooler, and Hinesville, from our three office locations.

This page explains how semaglutide works, what the FDA-approved treatment pathway looks like, who may be a candidate, what to expect during treatment, and how Scale Solutions manages your care from your first dose through long-term follow-up. To schedule a consultation, call (912) 352-7546.

What Is Semaglutide?

Semaglutide is a synthetic analog of GLP-1, a naturally occurring hormone produced in the intestinal tract in response to food intake. GLP-1 plays several regulatory roles in the body’s metabolic response to eating—it stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. Semaglutide mimics these effects by binding to and activating GLP-1 receptors in the pancreas, gut, liver, and brain.

The medication was originally developed for type 2 diabetes management (under the brand name Ozempic®) and was subsequently studied and approved at a higher dose for chronic weight management (Wegovy®). Both are the same molecule; the distinction lies in dose, approved indication, and labeling.

FDA Approval Status

• Ozempic® (semaglutide 0.5 mg, 1 mg, 2 mg): FDA-approved for glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Not FDA-approved specifically for weight management.
• Wegovy® (semaglutide 2.4 mg): FDA-approved for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia), in conjunction with a reduced-calorie diet and increased physical activity.

Scale Solutions prescribes semaglutide within the framework of these FDA approvals. We do not prescribe compounded semaglutide. The FDA has issued guidance regarding the risks of compounded GLP-1 medications, and we believe the consistent manufacturing quality and clinical data behind FDA-approved brand-name products represent the appropriate standard of care.

How Semaglutide Works for Weight Management

Semaglutide produces weight loss through several interconnected mechanisms:

1. Appetite Regulation

GLP-1 receptors are present in the hypothalamus and other brain regions involved in hunger and satiety signaling. Semaglutide activates these central receptors, reducing appetite and increasing the feeling of fullness (satiety) that follows meals. Patients often report that food simply becomes less compelling—smaller portions feel satisfying, and cravings diminish. This is a pharmacological effect, not a matter of willpower.

2. Slowed Gastric Emptying

Semaglutide slows the rate at which food moves from the stomach into the small intestine. This contributes to prolonged feelings of fullness after eating and can reduce overall caloric intake. It also explains one of the most common early side effects: nausea, particularly in the first weeks of treatment or following dose increases.

3. Glucose Regulation

By stimulating insulin secretion in response to elevated blood glucose and suppressing inappropriate glucagon release, semaglutide improves glycemic control in patients with type 2 diabetes or insulin resistance. For patients with pre-diabetes or metabolic syndrome, this can be a meaningful additional benefit of GLP-1 therapy alongside weight reduction.

Who Is a Candidate for Semaglutide at Scale Solutions?

FDA label criteria for Wegovy® (semaglutide for weight management) require:

• BMI ≥ 30 kg/m², or
• BMI ≥ 27 kg/m² with at least one weight-related comorbidity

In clinical practice, candidacy evaluation also considers your full medical history. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). It is not recommended during pregnancy or active breastfeeding. Patients with pancreatitis history, diabetic retinopathy, or severe gastrointestinal disease require careful evaluation before initiating therapy.

Dr. Gates will review your complete history at your consultation before making any prescribing recommendation. The goal is not simply to prescribe—it is to ensure the medication is appropriate, safe, and likely to benefit you.

Dosing Titration Schedule

Semaglutide at the Wegovy® dose is initiated at a low dose and increased gradually over approximately 16 to 20 weeks to allow the body to adapt and minimize gastrointestinal side effects. The standard titration follows this general progression:

• Weeks 1–4: 0.25 mg once weekly (initiation dose; sub-therapeutic for weight loss, used for tolerability)
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 and beyond: 2.4 mg once weekly (target maintenance dose)

Semaglutide is administered by subcutaneous injection once weekly. Dr. Gates will train you on proper injection technique at your first treatment visit. Injections can be self-administered at home.

Note: Dose titration may be adjusted based on tolerability. If you experience significant side effects at a dose increase, Dr. Gates may recommend remaining at a lower dose for a longer period before advancing. Rapid titration to minimize time to therapeutic dose is not the priority—tolerability and safety are.

Side Effects: What to Expect

The most common side effects of semaglutide are gastrointestinal in nature and are most pronounced during the titration phase:

• Nausea: The most common side effect, particularly in the first weeks of a new dose. Typically improves over days to weeks as the body adapts.
• Constipation: Slowed gastric motility affects the entire GI tract. Adequate hydration and dietary fiber are important countermeasures.
• Vomiting and diarrhea: Less common than nausea but reported in some patients, especially if meals are too large.
• Fatigue: Some patients report mild fatigue early in treatment.
• Injection site reactions: Mild redness or discomfort at the injection site; generally minor and transient.

Serious adverse events are rare but include pancreatitis, gallbladder disease, and a theoretical risk of thyroid tumors (based on animal studies; significance in humans is not established). Dr. Gates discusses these risks with each patient during the informed consent process.

What to Eat (and What to Avoid) on Semaglutide

GLP-1 therapy changes how your body responds to food. To support tolerability and maximize results:

• Eat protein-forward, smaller meals: Because gastric emptying is slowed, large meals can exacerbate nausea. Small meals rich in protein (lean meats, eggs, legumes, Greek yogurt) help maintain satiety and muscle mass.
• Avoid high-fat, high-sugar foods: Fatty meals and sugary drinks tend to worsen nausea in GLP-1 users. They also undermine the metabolic goals of treatment.
• Maintain adequate hydration: Constipation management begins with hydration. Aim for at least 64 ounces of water daily.
• Do not skip doses: Missed doses disrupt the steady-state pharmacology of semaglutide and can lead to increased side effects when doses are resumed. If a dose is missed, follow the prescribing instructions regarding when to take it or skip it.
• Do not attempt rapid dose escalation: Increasing your dose faster than the titration schedule does not accelerate weight loss and substantially increases GI side effects. Always advance the dose only as directed by Dr. Gates.

Monitoring at Scale Solutions

Your progress at Scale Solutions is monitored by Dr. Gates through regular follow-up appointments. Typical monitoring includes:

• Weight and vital signs at each visit
• Assessment of side effects and tolerability
• Review of dietary and activity patterns
• Laboratory monitoring as clinically indicated (which may include metabolic panel, HbA1c, lipids, and thyroid panel depending on your history)
• Dose adjustment decisions made by Dr. Gates, not auto-escalated by a protocol

Patients who have concerns between scheduled visits can contact our office. Clinical questions are addressed by Dr. Gates, not by automated messaging systems or non-physician staff working from scripts.

FDA-Approved vs. Compounded Semaglutide: Why It Matters

Compounded semaglutide is produced by compounding pharmacies outside the FDA drug approval process. While compounding has legitimate uses in medicine, compounded medications are not held to the same manufacturing quality, purity, and potency standards as FDA-approved drugs. The FDA has received reports of adverse events associated with compounded GLP-1 products and has taken regulatory action against some compounding operations.

Scale Solutions does not prescribe compounded semaglutide or compounded tirzepatide. We prescribe Ozempic®, Wegovy®, Mounjaro®, and Zepbound® exclusively. This is not a business decision—it reflects Dr. Gates’ clinical judgment that FDA-approved products represent the appropriate standard of care for our patients.

Cost and Insurance

The cost of semaglutide therapy involves two components: the clinical program (visits, monitoring) and the medication itself.

Wegovy® list prices are substantial, and out-of-pocket costs depend heavily on insurance coverage. Some commercial plans cover Wegovy® for obesity; others exclude it. Medicare currently has limited coverage for weight management medications, though the regulatory landscape is evolving. Manufacturer savings programs (such as the Novo Nordisk savings card) may reduce cost for eligible commercially insured patients.

Scale Solutions’ program visit pricing is published transparently on our Pricing page. We are happy to assist you understand your medication cost before committing to treatment. For patients for whom semaglutide cost is a significant barrier, Dr. Gates may discuss whether tirzepatide (Zepbound®) represents a clinically appropriate alternative given your coverage situation. See our Tirzepatide page for details.

Frequently Asked Questions — Semaglutide